Timothy N. C. Wells MA, PhD, ScD

Dr. Timothy Wells has been Chief Scientific Officer of Medicines for Malaria Venture (MMV) since 2007, building and managing a portfolio of new medicines from discovery through to post-approval studies. In collaboration with a wide network of partners, MMV has launched seven products over this period, which are used to treat millions of children annually. From 1997 to 2006, he was head of Research for Seron the Swiss biotech company where he was responsible for developing products in oncology, neurology, immunology, and reproductive health. Beyond MMV, he advises on a variety of infectious disease projects and is a non-executive director at Kymab, with a personal interest in applying antibody technology in infectious disease.

Dr. Wells earned a Doctor of Philosophy in Chemistry from Imperial College London in the UK with a focus on engineering enzyme transition states and a Doctor of Science in Biology from Cambridge University in the UK, with a focus on cytokine biology. Wells is a fellow of the UK’s Royal Society of Chemistry and Academy of Medical Sciences.